AKT1 is altered in 0.37% of bile duct carcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is altered in 1.51% of bile duct carcinoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM is altered in 5.83% of bile duct carcinoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATR is altered in 2.24% of bile duct carcinoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is altered in 5.02% of bile duct carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA1 is altered in 1.73% of bile duct carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for bile duct carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and bile duct carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRCA2 is altered in 3.87% of bile duct carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for bile duct carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and bile duct carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CCND1 is altered in 2.81% of bile duct carcinoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is altered in 2.23% of bile duct carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK4 is altered in 0.67% of bile duct carcinoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is altered in 1.36% of bile duct carcinoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A is altered in 14.62% of bile duct carcinoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 is altered in 0.45% of bile duct carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CSF1R is altered in 1.04% of bile duct carcinoma patients [2].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is altered in 2.41% of bile duct carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 4.07% of bile duct carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 3 clinical trials for bile duct carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 status and bile duct carcinoma as inclusion criteria, 3 are phase 2 (2 open) [3].

ERBB3 is altered in 3.72% of bile duct carcinoma patients [2].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EXO1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is altered in 1.99% of bile duct carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is altered in 0.68% of bile duct carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is altered in 10.72% of bile duct carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR3 is altered in 2.17% of bile duct carcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is altered in 1.18% of bile duct carcinoma patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 1.24% of bile duct carcinoma patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is altered in 1.81% of bile duct carcinoma patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is altered in 15.57% of bile duct carcinoma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and bile duct carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KDR is altered in 1.63% of bile duct carcinoma patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is altered in 1.12% of bile duct carcinoma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MET is altered in 1.7% of bile duct carcinoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH1 is altered in 1.01% of bile duct carcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH3 is altered in 2.84% of bile duct carcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is altered in 0.48% of bile duct carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is altered in 1.07% of bile duct carcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH3 is altered in 0.99% of bile duct carcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 1.99% of bile duct carcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MST1R is altered in 0.72% of bile duct carcinoma patients [2].

MST1R is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is altered in 0.91% of bile duct carcinoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN is altered in 1.44% of bile duct carcinoma patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRG1 is altered in 0.46% of bile duct carcinoma patients [2].

NRG1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is altered in 2.34% of bile duct carcinoma patients [2].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK2 is altered in 0.33% of bile duct carcinoma patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is altered in 1.88% of bile duct carcinoma patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is altered in 1.61% of bile duct carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PCNA is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 0.75% of bile duct carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is altered in 1.23% of bile duct carcinoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is altered in 5.01% of bile duct carcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS1 is altered in 0.74% of bile duct carcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 0.8% of bile duct carcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLD1 is altered in 1.68% of bile duct carcinoma patients [2].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 2.75% of bile duct carcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C is altered in 0.77% of bile duct carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is altered in 0.55% of bile duct carcinoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is altered in 1.77% of bile duct carcinoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ROS1 is altered in 1.92% of bile duct carcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC1 is altered in 2.65% of bile duct carcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 is altered in 1.53% of bile duct carcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VHL is altered in 0.19% of bile duct carcinoma patients [2].

VHL is an inclusion eligibility criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].